Market Overview

UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts

Related ACOR
Events for the Week of Sept. 8-12
Will Teva Pharmaceutical (TEVA) Beat Q2 Earnings Estimates?

Citigroup raised its rating on Acorda Therapeutics (NASDAQ: ACOR) from Neutral to Buy and raised its price target from $28 to $33.

Citigroup said, "We expect Ampyra to continue to grow fueled by modest market share gains and price increases. We project a 10% price increase in Q1:13 and 5% annually thereafter as there is still pricing power for the brand. This is overlooked by investors and should drive Ampyra's growth. We see limited downside to the stock as the stock is undervalued based on DCF esp. after its poor performance in 2012."

Acorda Therapeutics closed at $24.86 on Wednesday.

Latest Ratings for ACOR

DateFirmActionFromTo
May 2014CitigroupMaintainsHold
Apr 2014Canaccord GenuityInitiates Coverage onHold
Apr 2014FBR CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for ACOR
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ACOR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional